High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on year to $7.80 billion. On the other hand, the company’s full-year revenue guidance of $30.25 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP loss of $6.75 per share was 6.9% above analysts’ consensus estimates.
Gilead Sciences narrowly beat sales expectations for HIV PrEP drug Yeztugo. But Gilead stock remains trapped below two key lines.
By Deena Beasley Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss due to costs
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
You don't need to predict a recession to prepare your portfolio. These two stocks can help.
Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Cheap Stocks to Buy Right Now. On June 30, Morgan Stanley kept its Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and maintained its price target of $168. The research firm’s positive view is based on a number of factors, including the company’s growth outlook […]
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate […]
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group. Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung cancer trial...
Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy […]
Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $133.73 as of May 26th. GILD’s trailing and forward P/E were 18.19 and 15.22 respectively according to Yahoo […]
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]
Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Stocks to Invest In. On May 22, 2026, the U.S. Food and Drug Administration approved Hepcludex injection, granted to Gilead Sciences, Inc. (NASDAQ:GILD), to treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis. The FDA said bulevirtide is the […]
With an annual dividend yield of 2.50%, Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. On May […]
U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.
With a net income margin of 31.00% and upside potential of 24.20%, Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best extremely profitable stocks to buy according to Wall Street analysts. The company reported net income of $8.51 billion for the recently completed fiscal year (FY25). That momentum continued into 2026, drawing analyst attention. On May […]
Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look. The Moderna Story Has Not Changed Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three ... Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company reported first-quarter revenue ahead of analyst expectations, despite posting a slightly wider-than-expected quarterly loss.
Gilead Sciences (GILD) is back in focus after a busy stretch that combined stronger than expected first quarter results, sharply revised full year loss guidance tied to acquisition related charges, and a priority FDA review for a new HIV regimen. See our latest analysis for Gilead Sciences. Even with the recent news flurry around Q1 results, revised guidance and fresh bond issues, Gilead Sciences' share price has eased in the short term, with a 30 day share price return of 7.29% and a 90 day...
Spiking energy prices have pushed inflation to a three-year high of 3.8%. Investors expect price pressures related to the Iran war to ease—one reason the stock market keeps chugging along. Retirees who collect Social Security should get a bigger raise next year.
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
